[go: up one dir, main page]

WO2000059491A3 - Methods for modulating the human sexual response - Google Patents

Methods for modulating the human sexual response Download PDF

Info

Publication number
WO2000059491A3
WO2000059491A3 PCT/US2000/009112 US0009112W WO0059491A3 WO 2000059491 A3 WO2000059491 A3 WO 2000059491A3 US 0009112 W US0009112 W US 0009112W WO 0059491 A3 WO0059491 A3 WO 0059491A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
sexual response
methods
phentolamine
human sexual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/009112
Other languages
French (fr)
Other versions
WO2000059491A2 (en
Inventor
Andrian Di Zorgniotti
Joseph S Podolski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repros Therapeutics Inc
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00921760A priority Critical patent/EP1220666A2/en
Priority to KR1020017012674A priority patent/KR20020015310A/en
Priority to MXPA01010021A priority patent/MXPA01010021A/en
Priority to AU42036/00A priority patent/AU4203600A/en
Priority to JP2000609055A priority patent/JP2002541100A/en
Priority to BR0009583-4A priority patent/BR0009583A/en
Application filed by Zonagen Inc filed Critical Zonagen Inc
Priority to CA002366903A priority patent/CA2366903A1/en
Publication of WO2000059491A2 publication Critical patent/WO2000059491A2/en
Priority to NO20014827A priority patent/NO20014827L/en
Anticipated expiration legal-status Critical
Publication of WO2000059491A3 publication Critical patent/WO2000059491A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is directed to improved methods for modulating the human sexual response by administering a vasodilator, selected from the group consisting of phentolamine, phentolamine mesylate, phentolamine hydrochloride, apomorphine, phenoxybenzamine, nitroglycerin, thymoxamine, nicotinyl alcohol, imipramine, verapamil, isoxsuprine, naftidrofuryl, tolazoline and papaverine, to the circulation through transmucosal, including but not limited to, administration through the vaginal mucosa, transdermal, intranasal or rectal routes of administration.
PCT/US2000/009112 1999-04-06 2000-04-06 Methods for modulating the human sexual response Ceased WO2000059491A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020017012674A KR20020015310A (en) 1999-04-06 2000-04-06 Methods for modulating the human sexual response
MXPA01010021A MXPA01010021A (en) 1999-04-06 2000-04-06 Methods for modulating the human sexual response.
AU42036/00A AU4203600A (en) 1999-04-06 2000-04-06 Methods for modulating the human sexual response
JP2000609055A JP2002541100A (en) 1999-04-06 2000-04-06 Methods for modulating human sexual response
BR0009583-4A BR0009583A (en) 1999-04-06 2000-04-06 Methods to modulate the sexual response in a human, and for the manufacture of a drug to modulate the sexual response in a human
EP00921760A EP1220666A2 (en) 1999-04-06 2000-04-06 Methods for modulating the human sexual response
CA002366903A CA2366903A1 (en) 1999-04-06 2000-04-06 Methods for modulating the human sexual response
NO20014827A NO20014827L (en) 1999-04-06 2001-10-04 Procedures for modulating human sexual response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12791099P 1999-04-06 1999-04-06
US60/127,910 1999-04-06

Publications (2)

Publication Number Publication Date
WO2000059491A2 WO2000059491A2 (en) 2000-10-12
WO2000059491A3 true WO2000059491A3 (en) 2002-05-02

Family

ID=22432589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009112 Ceased WO2000059491A2 (en) 1999-04-06 2000-04-06 Methods for modulating the human sexual response

Country Status (10)

Country Link
EP (1) EP1220666A2 (en)
JP (1) JP2002541100A (en)
KR (1) KR20020015310A (en)
CN (1) CN1374861A (en)
AU (1) AU4203600A (en)
BR (1) BR0009583A (en)
CA (1) CA2366903A1 (en)
MX (1) MXPA01010021A (en)
NO (1) NO20014827L (en)
WO (1) WO2000059491A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130704D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd New use
US8939889B1 (en) 2013-08-22 2015-01-27 Coloplast A/S Pump bulb for an implantable penile prosthetic

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346297A1 (en) * 1988-06-08 1989-12-13 CENTRO MEDICO HARVEY S.r.l. A preparation for topical use in the therapeutic treatment of impotentia coeundi
WO1995005172A1 (en) * 1993-08-13 1995-02-23 Zonagen, Inc. Methods for modulating the human sexual response
WO1998043614A1 (en) * 1997-03-28 1998-10-08 Lam Pharmaceuticals, Llc Drug preparations for treating sexual dysfunction
WO1998052569A1 (en) * 1997-05-19 1998-11-26 Zonagen, Inc. Combination therapy for modulating the human sexual response
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US5981563A (en) * 1995-04-28 1999-11-09 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1999065475A2 (en) * 1998-06-19 1999-12-23 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2000013664A1 (en) * 1998-09-08 2000-03-16 L.A.M. Pharmaceutical Corp Drug preparations for treating sexual dysfunction
WO2000033825A2 (en) * 1998-12-10 2000-06-15 Nexmed Holdings, Inc. Compositions and methods for amelioration of human female sexual dysfunction

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346297A1 (en) * 1988-06-08 1989-12-13 CENTRO MEDICO HARVEY S.r.l. A preparation for topical use in the therapeutic treatment of impotentia coeundi
WO1995005172A1 (en) * 1993-08-13 1995-02-23 Zonagen, Inc. Methods for modulating the human sexual response
US5981563A (en) * 1995-04-28 1999-11-09 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1998043614A1 (en) * 1997-03-28 1998-10-08 Lam Pharmaceuticals, Llc Drug preparations for treating sexual dysfunction
WO1998052569A1 (en) * 1997-05-19 1998-11-26 Zonagen, Inc. Combination therapy for modulating the human sexual response
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
WO1999065475A2 (en) * 1998-06-19 1999-12-23 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2000013664A1 (en) * 1998-09-08 2000-03-16 L.A.M. Pharmaceutical Corp Drug preparations for treating sexual dysfunction
WO2000033825A2 (en) * 1998-12-10 2000-06-15 Nexmed Holdings, Inc. Compositions and methods for amelioration of human female sexual dysfunction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERMAN J R ET AL: "FEMALE SEXUAL DYSFUNCTION: INCIDENCE, PATHOPHYSIOLOGY, EVALUATION, AND TREATMENT OPTIONS", UROLOGY,US,BELLE MEAD, NJ, vol. 54, September 1999 (1999-09-01), pages 385 - 391, XP000891790, ISSN: 0090-4295 *
GOLDSTEIN I ET AL: "VASCULOGENIC FEMALE SEXUAL DYSFUNCTION: VAGINAL ENGORGEMENT AND CLITORAL ERECTILE INSUFFICIENCY SYNDROMES", INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH,GB,STOCKTON, BASINGSTOKE, vol. 10, no. SUPPL. 02, May 1998 (1998-05-01), pages S84 - S90, XP000853842, ISSN: 0955-9930 *
PAYNE, ELIZABETH ET AL: "A comparison of prostaglandin E-2 vaginal tablets with vaginal gel for ripening the unfavourable cervix and induction of labour.", JOURNAL OF OBSTETRICS AND GYNAECOLOGY (ABINGDON), (1993) VOL. 13, NO. 2, PP. 103-106., XP000997664 *
QURESHI, AASIM: "Vasomax Zonagen", CURR. OPIN. CENT. PERIPHER. NERV. SYST. INVEST. DRUGS (1999), 1(2), 262-267, XP000989426 *
ZORGNIOTTI A W: "EXPERIENCE WITH BUCCAL PHENTOLAMINE MESYLATE FOR IMPOTENCE", INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH,GB,STOCKTON, BASINGSTOKE, vol. 6, no. 1, 1 March 1994 (1994-03-01), pages 37 - 41, XP000653737, ISSN: 0955-9930 *

Also Published As

Publication number Publication date
AU4203600A (en) 2000-10-23
CN1374861A (en) 2002-10-16
JP2002541100A (en) 2002-12-03
KR20020015310A (en) 2002-02-27
EP1220666A2 (en) 2002-07-10
CA2366903A1 (en) 2000-10-12
NO20014827L (en) 2001-12-04
MXPA01010021A (en) 2002-07-30
NO20014827D0 (en) 2001-10-04
WO2000059491A2 (en) 2000-10-12
BR0009583A (en) 2002-06-11

Similar Documents

Publication Publication Date Title
JP5401502B2 (en) Cell necrosis inhibitor
EP1177190B1 (en) USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
KR20110036583A (en) 6-1H-imidazo-quinazolin and quinoline derivatives, new MAO inhibitors and imidazoline receptor ligands
KR960703588A (en) METHODS FOR MODULATION THE HUMAN SEXUAL RESPONSE
KR20040048995A (en) Quinoline compound
PT1337535E (en) BENZODIAZEPINE DERIVATIVES
EA200601852A1 (en) TETRAHYDROCHINOLINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
PL363079A1 (en) Transdermal patch for administering fentanyl
JP2003506347A5 (en)
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
EP0511477B1 (en) Indole derivatives
KR100226954B1 (en) Piperidinyl benzimidazole derivatives, the pharmaceutical composition containing them and the process of them
TR200200263T2 (en) New selective retinoid agonists
WO2000059491A3 (en) Methods for modulating the human sexual response
EP1667976A4 (en) INHIBITORS OF POTASSIUM CANAL BASED ON ISOQUINOLINONE
Reimann et al. A convenient synthesis of 1-benzyl-1, 2, 3, 4-tetrahydroisoquinolines by combined Strecker/Bruylants reaction
US4321254A (en) Antiallergic imidodisulfamides
EA200000322A1 (en) METHOD FOR SYNTHESIS OF QUINOLINE DERIVATIVES
KR20030060968A (en) Farnesyltransferase inhibitors
KR100856141B1 (en) Benzazepine derivatives as mao-b inhibitors
NO20024198L (en) Process for the preparation of citalopram
ATE399164T1 (en) ANTAGONISTS OF THE OPIOID RECEPTOR
TR200401864T4 (en) Process for preparing quinolylacrylonitrile and its intermediates
KR20060125000A (en) 3,4-dihydroisoquinolinium salt derivative
PT1392672E (en) THYOPHENE CHLOROMETHYL ACETATE

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807879.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN ES IL JP KR MX NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2366903

Country of ref document: CA

Ref document number: 2366903

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010021

Country of ref document: MX

Ref document number: 1020017012674

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 609055

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000921760

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 515296

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09937879

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000921760

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000921760

Country of ref document: EP